Biogen's Litifilimab Shows Durable CLE Results at 52 Weeks

Biogen Inc. on Thursday unveiled 52-week results from the Phase 2 portion of its ongoing AMETHYST Phase 2/3 trial evaluating litifilimab in patients with cutaneous lupus erythematosus, a chronic autoimmune condition that primarily attacks the skin. The findings, presented at the European Academy of Dermatology and Venereology Congress in Vienna, Austria, represent the longest dataset yet reported for the experimental drug in this indication.

Participants who received litifilimab throughout the double-blind, placebo-controlled period maintained continuous clinical improvements in skin disease activity through the 52-week mark, according to the Cambridge, Massachusetts-based biotechnology company. Biogen characterized the results as evidence that the therapy can deliver both rapid onset and lasting benefit — a combination that has proven difficult to achieve in autoimmune dermatology.

Read more Corgi Insurance Unveils Specialized Data Center Coverage Program →

Perhaps the most clinically notable finding involved participants who had been on placebo and crossed over to active treatment at Week 24. That subgroup began showing measurable responses within four weeks of initiating litifilimab, suggesting the drug acts quickly even in patients who had not previously received it. Analysts tracking the lupus pipeline have long noted that speed of response is a key differentiator in competitive drug development for CLE.

Litifilimab targets a biological pathway implicated in the inflammatory cascade underlying lupus skin disease, and Biogen has positioned it as a potential first-in-class therapy for CLE. The AMETHYST study continues into its Phase 3 portion, which will be needed to support any eventual regulatory submission. No serious new safety signals were highlighted in the company's announcement of the Phase 2 data.

Continue reading at GlobeNewswire - Industry News on Financial Services.